This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

The challenges involved in developing a peptide in tablet form include overcoming the stomach’s enzymatic breakdown and increasing absorption across the gastric epithelium. It took a suitable GLP-1 RA molecule – semaglutide – and an absorption enhancer to make the world’s first oral GLP-1 RA a reality. 

 

Watch this 3-minute video to see how RYBELSUS® works.

GLP-1 RAs mimic how the body naturally responds to blood glucose, working when the body needs it.1

 

Use of the GLP-1 RA class is supported by internationally recognised associations. The ADA/EASD type 2 diabetes management consensus report recommends GLP-1 RA therapies for glycaemic control.2,3

RYBELSUS® innovation story

Learn about the challenges involved in developing a peptide in tablet form.
PIONEER clinical trial

A global Phase 3 clinical trial programme investigating oral semaglutide.
RYBELSUS® efficacy and safety

RYBELSUS® has been studied across 10 phase 3 clinical trials in over 9,000 patients.

1.

RYBELSUS® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/S; April 2023. 

2.

Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498.

3.

Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2019;63(2):221-228.

4.

Connor A, Donsmark M, Hartoft-Nielsen M-L, Søndergaard F, Bækdal TA. A pharmacoscintigraphic study of the relationship between tablet erosion and pharmacokinetics of oral semaglutide. Poster presented at the European Association for the Study of Diabetes (EASD): 11-15 September 2017; Lisbon, Portugal.

 

FOR HEALTHCARE PROFESSIONALS ONLY

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness, or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.
 

HQ21RYB00036 August 2021